Benefit of Surveillance for Pancreatic Cancer in High-Risk Individuals: Outcome of Long-Term Prospective Follow-Up Studies From Three European Expert Centers

Benefit of Surveillance for Pancreatic Cancer in High-Risk Individuals: Outcome of Long-Term Prospective Follow-Up Studies From Three European Expert Centers

Surveillance of CDNK2A mutation carriers is relatively successful, detecting most PDACs at a resectable stage. The benefit of surveillance in families with FPC is less evident. (C) 2016 by American Society of Clinical Oncology

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of Clinical Oncology 2016-06, Vol.34 (17), p.2010-+
Hauptverfasser: Vasen, H., Ibrahim, I., Ponce, C.G., Slater, E.P., Matthai, E., Carrato, A., Earl, J., Robbers, K., Mil, A.M. van, Potjer, T., Bonsing, B.A., Cappel, W.H.D.T.N., Bergman, W., Wasser, M., Morreau, H., Kloppel, G., Schicker, C., Steinkamp, M., Figiel, J., Esposito, I., Mocci, E., Vazquez-Sequeiros, E., Sanjuanbenito, A., Munoz-Beltran, M., Montans, J., Langer, P., Fendrich, V., Bartsch, D.K.
Format: Artikel
Sprache:eng
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Surveillance of CDNK2A mutation carriers is relatively successful, detecting most PDACs at a resectable stage. The benefit of surveillance in families with FPC is less evident. (C) 2016 by American Society of Clinical Oncology
DOI:10.1200/JCO.2015.64.0730